Feedback
Settings

Settings

Goto Application

280,847 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,085
1.WO/2026/012477DSRNA, USE THEREOF, AND METHOD FOR PREPARING SAME
WO - 15.01.2026
Int.Class A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
 Appl.No PCT/CN2025/108176 Applicant INNOVENT BIOLOGICS (SUZHOU) CO., LTD. Inventor WANG, Yanhui
The present invention relates to a modulator, such as a double-stranded RNA (dsRNA) active agent or an antisense polynucleotide formulation, that can modulate, e.g., inhibit, the expression and/or activity of cell death-inducing DFFA-like effector B (CIDEB). The present invention also relates to a method for inhibiting CIDEB expression and/or activity using such a modulator, and a method for preventing and treating a CIDEB-related disease (such as a chronic inflammatory disease) in a subject.
2.WO/2026/012491COMPOUND COMPRISING LIPOPHILIC MONOMER FOR DELIVERY TO EYES AND CENTRAL NERVOUS SYSTEM, AND USE THEREOF
WO - 15.01.2026
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/CN2025/108268 Applicant BEIJING WINSUNNY PHARMACEUTICAL CO., LTD Inventor WANG, Shucheng
One aspect of the present invention relates to a compound, wherein the compound is an oligonucleotide, and the compound comprises at least one lipophilic monomer. Another aspect of the present invention relates to a method for gene silencing, wherein the method comprises administering to a cell or a subject in need thereof a therapeutically effective amount of a compound conjugated with a lipophilic monomer.
3.WO/2026/0143655’ CAP ANALOG
WO - 15.01.2026
Int.Class C07H 19/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
 Appl.No PCT/JP2025/024109 Applicant NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM Inventor ABE, Hiroshi
Provided is a technique for more easily obtaining a 5’ capped polynucleotide which is purified and exhibits high translation activity. The 5' cap analog is characterized in that a hydroxy group at the 2’ and/or 3’ position of ribose contained in 7-methylguanylic acid is substituted with a non-photodegradable hydrophobic protecting group.
4.WO/2026/014409METHOD FOR PRODUCING ALKYLATED URACIL DERIVATIVE
WO - 15.01.2026
Int.Class C07D 405/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/JP2025/024319 Applicant AGC INC. Inventor NOMURA, Yoshitaka
Provided is a method for synthesizing an N1-alkylated uracil derivative from a uracil derivative by one step, comprising a step for synthesizing, from a compound represented by general formula (1), a compound represented by general formula (2) by an alkylation reaction in the presence of a TMS group-containing compound. [In the formulas, is a hydrogen atom, an alkali metal atom, or -P(=O)(OR11)(OR12) (where R11 and R12 each independently represent a monovalent cation, an alkyl group which may have a substituent, or an acyl group); the ring A represents a 5- to 8-membered ring; when R1 is other than a hydrogen atom, the ring A is substituted with at least one hydroxy group; R2 is a group including a structure represented by formula (r2); and R3 represents a group including a structure represented by formula (r3) (where R31 is an alkyl group).]
5.WO/2026/015080LINKAGE GROUPS, OLIGONUCLEOTIDE CONJUGATES, AND METHODS THEREOF
WO - 15.01.2026
Int.Class C07H 9/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
9Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
02the hetero ring containing only oxygen as ring hetero atoms
04Cyclic acetals
 Appl.No PCT/SG2025/050460 Applicant AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Inventor YING, Jackie Yi-ru
This disclosure concerns linkage groups and uses thereof for conjugating ligands to nucleic acids. Also provided are oligonucleotide-ligand conjugates containing the linkage group, and uses thereof for targeted nucleic acid delivery and as a medicament.
6.WO/2026/015078ACTIVATABLE FLUORESCENT PROBES FOR OPTICAL URINALYSIS OF KIDNEY DISEASE
WO - 15.01.2026
Int.Class C07H 17/075
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
06Benzopyran radicals
065Benzopyrans
075Benzopyran-2-ones
 Appl.No PCT/SG2025/050458 Applicant NANYANG TECHNOLOGICAL UNIVERSITY Inventor PU, Kanyi
The current invention relates to compounds suitable for detecting the presence of N-Acetyl-β- D-glucosaminidase (NAG). The current invention further relates to methods of detecting the NAG in a sample obtained from a subject suspected of having increased levels of NAG comprising a step of providing a formulation comprising the compounds.
7.20260008806TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION
US - 08.01.2026
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No 19085460 Applicant WAVE LIFE SCIENCES LTD. Inventor Keith Andrew Bowman

Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

8.WO/2026/007963MACROPHAGE-TARGETING COMPOUND AND USE THEREOF
WO - 08.01.2026
Int.Class C07H 15/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
 Appl.No PCT/CN2025/106469 Applicant FUDAN UNIVERSITY Inventor CHEN, Guosong
The present invention relates to the technical field of biology, and specifically relates to a macrophage-targeting compound and a use thereof. The compound uses a saccharide as a raw material, and the problem of functional instability caused by the non-uniform structural composition of the compound is avoided while the high targeting performance of the compound is maintained. By selecting the basic unit of a saccharide as a targeting moiety and then linking to a hydrophobic chain, the aggregation of saccharide units in water is completed, ensuring the high targeting performance of the design material. The saccharide-containing compound and a complex thereof can specifically target macrophages in plaques without affecting other cells, thereby achieving in vivo specific targeting of macrophages.
9.WO/2026/007903QUINOLONE DERIVATIVE OF MACROLIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 08.01.2026
Int.Class C07H 17/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
08Hetero rings containing eight or more ring members, e.g. erythromycins
 Appl.No PCT/CN2025/105698 Applicant BEIJING INSTITUTE OF TECHNOLOGY Inventor LIANG, Jianhua
Provided are a compound represented by formula (I), a stereoisomer, tautomer, isotopic marker, nitrogen oxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition. The compound has good antibacterial and anti-inflammatory effects, can be used as an antibiotic, can treat infections caused by pathogenic microorganisms resistant to erythromycin and telithromycin, and simultaneously acts on two targets, i.e., ribosomes and topoisomerase.
10.WO/2026/010948COMPOUNDS USEFUL FOR THE TREATMENT OF DISORDERS AND METHODS RELATED THERETO
WO - 08.01.2026
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/US2025/036081 Applicant OTSUKA AMERICA PHARMACEUTICAL, INC. Inventor SLASSI, Abdelmalik
The present disclosure relates to naphthylethylamine, quinolylethylamine, isoquinolynethylamine, and cinnolynethylamine derivative compounds of general Formula (I), to processes for their preparation, to compositions including naphthylethylamine, quinolylethylamine, isoquinolynethylamine, and cinnolynethylamine derivative compounds of general Formula (I), and to their use for treating diseases, disorders, or conditions. The diseases, disorders, or conditions include, for example, mental illnesses and neurological disorders.
# -